Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SINGLE: Dolutegravir + Abacavir/Lamivudine vs Atripla in HIV-1
NCT01263015Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Feb 2011
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Feb 2011; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01263015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01263015.